Lannett Receives FDA Approval For Levofloxacin Oral Solution; Imminent Launch Anticipated

PHILADELPHIA, June 1, 2018 -- (Healthcare Sales & Marketing Network) -- Lannett Company, Inc. (NYSE: LCI) today announced that it received approval from the U.S. Food and Drug Administration (FDA) of its Abbreviated New Drug Application (ANDA) for Levoflo... Biopharmaceuticals, Generics, FDA, Product Launch Lannett Company, Janssen Pharmaceuticals, Levofloxacin, Levaquin
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news